The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of Myalgic Encephalomyelitis (ME/CFS): A Report from the European Network on ME/CFS (EUROMENE). — CFSMEATLAS
The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of Myalgic Encephalomyelitis (ME/CFS): A Report from the European Network on ME/CFS (EUROMENE).
Pheby, Derek F H, Araja, Diana, Berkis, Uldis et al. · Healthcare (Basel, Switzerland) · 2020 · DOI
Quick Summary
This study created a unified European system for measuring how much ME/CFS costs society in terms of healthcare, lost work, and other expenses. The researchers found that ME/CFS places a heavy financial burden on Europe, mostly because patients lose work productivity. However, they discovered that calculating these true costs is very difficult because different countries use different diagnostic criteria and many doctors don't diagnose ME/CFS, leaving many patients uncounted.
Why It Matters
Economic burden studies provide essential evidence for healthcare policy and resource allocation decisions. By establishing a consistent European methodology, this work enables researchers to generate comparable cost data across countries, which can strengthen advocacy efforts and justify investment in ME/CFS research, diagnosis, and treatment.
Observed Findings
ME/CFS places a substantial economic burden on Europe, with productivity losses identified as the most significant cost component.
Current economic studies of ME/CFS are problematic due to inconsistent case definitions and variable physician recognition of the diagnosis.
Undiagnosed patients represent an unknown but likely substantial portion of true economic burden that cannot be estimated with current methods.
Healthcare systems and economic development patterns vary significantly across European countries, complicating standardized cost comparisons.
Inferred Conclusions
Standardized case definitions (Fukuda and CCC) and systematic data collection methods are essential prerequisites for accurate economic burden assessment of ME/CFS across Europe.
Implementing common symptom checklists and agreed data lists will enable meaningful international comparisons of ME/CFS costs.
Improved physician training and diagnosis rates are necessary to capture the full economic impact including currently undiagnosed patients.
Remaining Questions
What are the actual incidence and prevalence rates of ME/CFS across different European countries when standardized diagnostic criteria are applied?
How much economic burden is attributable to undiagnosed and misdiagnosed patients across Europe?
What This Study Does Not Prove
This is a methodological framework paper, not a clinical trial or economic analysis itself. It does not provide actual economic cost estimates for ME/CFS or prove which treatments are cost-effective. It also does not establish prevalence rates or diagnose the reasons why physicians underdiagnose ME/CFS.